Seelos Therapeutics is dosing the first patient in an open-label basket study of SLS-005 in amyotrophic lateral sclerosis in Australia and is providing an enrollment update of its study on the HEALEY ALS platform | Pro Club Bd

Optimi will provide Bloom with sufficient biomass of natural psilocybin to begin conducting his previously announced clinical trial in partnership with the IMPACT Clinical Trial Accelerator Program, housed in Alberta’s Life Sciences Innovation Hub at the University of Calgary.

The proposed Phase I dosing study aims to find the optimal microdose, or low dose, of psilocybin that provides an overall improvement in mood, memory, sleep, and other measures of general well-being without hallucinogenic effects.

Jim Parker, Founder and CEO of Bloom says the partnership between Bloom and Optimi provides an incredible opportunity to measure true GMP-produced, Canadian-sourced natural psilocybin.

“Regulators in Canada and around the world are watching Canada’s nascent psychedelics industry and how it’s performing in terms of quality, safety and efficacy,” Parker said. “So I see this as an early tipping point where good therapeutic practices combined with Optimi’s natural Canadian GMP-grade psilocybin could establish Canada as a true leader among those looking to learn from us.”

Since completing its 20,000 square foot psilocybin cultivation and manufacturing facility in Princeton, British Columbia, Optimi has pursued a revenue-driven strategy of clinical therapy and research partnerships with the intention of developing logistical channels that will underpin the future of the psychedelics industry.

“To match Jim’s view of Canada defining itself as a leader in psychedelics, I believe the more Optimi produces, tests, and supplies studies and patients across the country, the more we will be able to establish the benchmarks needed for the development of a true cultivation Mecca in Canada and eventually the world,” added Ciprick.

Authorized parties interested in purchasing Optimi psilocybin and functional mushroom products, MDMA or other synthetic psychedelics are asked to contact where a member of the sales team will respond within 24 hours.


Optimi Health Corp. is a native Canadian success story aiming to become the world’s most trusted, compassionate supplier of safe, natural, EU-GMP psilocybin and functional mushrooms. The Company’s 20,000 square foot, state-of-the-art, technologically advanced in-house manufacturing and research facilities, built with the goal of manufacturing scalable, natural mushroom formulations for transformative human experiences, cultivate, test and synthesize high quality mushroom strains and psychedelic substances such as MDMA.

Based in Princeton, British Columbia, Optimi is developing a robust and innovative portfolio of IP through its Health Canada psilocybin dealer license.

Optimi’s vision is to unlock the regenerative power of mushrooms, advance psychedelic science and set the world’s highest standard for trusted GMP operational quality.

Optimi’s promise is to enable a future where natural psychedelic alternatives support a variety of mental illnesses.


The Bloom Psychedelic Therapy and Research Center is a world-class research center dedicated to advancing the science that supports the use of psychedelics for depression, suicidal thoughts, anxiety, PTSD, and chronic pain. We are proud to host the University of Calgary’s first research chair dedicated to this endeavor. The Parker Psychedelic Research Chair, led by the Mathison Center for Mental Health Research & Education at the Hotchkiss Brain Institute in the Cumming School of Medicine, advances important research into alternative therapies for mental health.


Investor Relations
Michael Kydd
Telephone: +1 (902) 880 6121


This press release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that reflect Optimi’s current expectations and beliefs about future events. Any statements expressing or discussing (often, but not always, through the use of words or phrases such as “is likely to result”, “expected to ‘, ‘expects’, ‘continues’, ‘is expected’, ‘anticipates’, ‘believes’, ‘estimates’, ‘intends’, ‘plans’, ‘forecasts’, ‘projection’, ‘strategy’, ‘objective and “Outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual outcomes or results to differ materially from those expressed in such forward-looking statements. There can be no assurance that these expectations will prove to be correct and undue reliance should not be placed on such forward-looking statements contained in this press release. These statements speak only as of the date of this press release. In particular, and without limitation, this press release contains forward-looking statements with respect to activities to be conducted under the Company’s dealer license and related business relating to psilocybin and psilocin and Optimi’s plans, priorities and goals.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those contained in or implied by the forward-looking statements. These risks and uncertainties include, among others, the impact and progression of the COVID-19 pandemic and other factors discussed under “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Information Form dated January 12, 2022, and other ongoing disclosure documents , which are available under Optimi’s profile at Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. New factors emerge from time to time and it is not possible for Optimi to predict all or the effects of each of these factors or the extent to which any one factor or combination of factors could cause results to differ materially from those included, to be evaluated in any forward-looking statement.

All forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Primary logo

Leave a Comment

Your email address will not be published.